论文部分内容阅读
目的:通过L-精氨酸治疗对妊娠高血压疾病合并胎儿生长受限相关因素的临床观察,探讨L-精氨酸对胎儿生长受限的治疗效果。方法:将妊娠高血压疾病合并胎儿生长受限患者60例,随机分为常规治疗组(A组)30例,L-精氨酸治疗组(B组)30例,另外20例正常妊娠组为对照组(C组),孕期定期用B型超声监测三组胎儿生长发育参数、脐血流参数,产后比较新生儿出生体重和围产儿结局。结果:①生长参数:治疗后A组与B组比较,B组双顶径(BPD)、股骨长(FL)及腹围(AC)的增长幅度较高,P<0.05。②脐血流参数:治疗后A组与B组比较,B组快速血流比值(FBVR)较高(P<0.05);B组搏动指数(PI)、阻力指数(RI)较低(P<0.05)。③新生儿出生体重和围产儿结局:B组的治愈率(73.3%),显著高于A组治愈率(43.3%)(P<0.05),新生儿平均出生体重高于A组,小于胎龄儿(SGA)的发生率低于A组。结论:L-精氨酸治疗较常规治疗疗效更显著,能更好地增加胎儿体重,促进胎儿发育,值得临床推广。
OBJECTIVE: To investigate the therapeutic effect of L-arginine on the growth restriction of fetus by L-arginine therapy in the treatment of pregnancy-induced hypertension with fetal growth restriction. Methods: 60 cases of pregnancy-induced hypertension with fetal growth restriction were randomly divided into routine treatment group (A group) 30 cases, L-arginine treatment group (B group) 30 cases, another 20 cases of normal pregnancy group The control group (C group), regular monitoring of fetal growth and development parameters, umbilical blood flow parameters by B ultrasound during pregnancy, neonatal birth weight and perinatal outcome after delivery. Results: (1) Growth parameters: After treatment, the growth of biparietal diameter (BPD), femur length (FL) and abdominal circumference (AC) in group B were higher than that in group B (P <0.05). (2) Umbilical blood flow parameters: The fasting blood flow ratio (FBVR) in group B was higher than that in group B after treatment (P <0.05), while the pulsatility index (PI) and resistance index (RI) 0.05). Neonatal birth weight and perinatal outcome: The cure rate of group B (73.3%) was significantly higher than that of group A (43.3%) (P <0.05). The average birth weight of newborns was higher than that of group A Children (SGA) lower than the incidence of A group. Conclusion: L-arginine treatment is more effective than conventional treatment, can better increase fetal weight and promote fetal development, worthy of clinical promotion.